Big Money Sentiment increased to 1.47 in Q3 2018. It has change of 0.16, from 2018Q2’s 1.31. The ratio is positive due to Revance Therapeutics, Inc. positioning: 10 sold and 22 reduced. 16 funds bought positions and 31 increased positions. Investors holded 32.89 million in 2018Q2 but now own 32.53 million shares or 1.08% less.
Cap Ww Invsts reported 1.23M shs. 2.55M are held by Franklin Res. 22,000 are owned by Hightower Advsrs Limited Liability Company. United Svcs Automobile Association has invested 0% in Revance Therapeutics, Inc. (NASDAQ:RVNC). Morgan Stanley accumulated 0% or 153,540 shs. Sio Cap Mngmt Ltd Com invested 1.4% of its capital in Revance Therapeutics, Inc. (NASDAQ:RVNC). Susquehanna Gru Ltd Liability Partnership holds 0% of its capital in Revance Therapeutics, Inc. (NASDAQ:RVNC) for 14,158 shs. Ny State Common Retirement Fund owns 36,500 shs for 0% of their capital. Barclays Public Limited holds 27,398 shs. Rhenman Prns Asset Mgmt invested in 0.51% or 203,181 shs. Bank Of Montreal Can stated it has 0% in Revance Therapeutics, Inc. (NASDAQ:RVNC). Citadel Advsrs Ltd Limited Liability Company has 116,669 shs. 10,592 were reported by State Board Of Administration Of Florida Retirement System. Rice Hall James And Assocs Lc reported 0.02% of its capital in Revance Therapeutics, Inc. (NASDAQ:RVNC). Prelude Mngmt Llc owns 0% invested in Revance Therapeutics, Inc. (NASDAQ:RVNC) for 200 shs.

Revance Therapeutics, Inc. registered $80,454 net activity with 0 insider buys and 4 sales since November 9, 2018.

Revance Therapeutics, Inc. (NASDAQ:RVNC) Ratings Coverage

In total 4 analysts cover Revance Therapeutics (NASDAQ:RVNC). “Buy” rating has 3, “Sell” are 0, while 1 are “Hold”. 75% are bullish. 4 are the (NASDAQ:RVNC)’s analyst reports since September 17, 2018 according to StockzIntelligence Inc. On Friday, November 16 the rating was upgraded by Guggenheim to “Buy”. On Monday, September 17 the firm has “Market Perform” rating by JMP Securities given. Listed here are Revance Therapeutics, Inc. (NASDAQ:RVNC) PTs and latest ratings.

14/02/2019 Broker: H.C. Wainwright Rating: Buy New Target: $25 Initiates Coverage On
29/01/2019 Broker: Stifel Nicolaus Rating: Buy New Target: $50 Initiates Coverage On
16/11/2018 Broker: Guggenheim Old Rating: Neutral New Rating: Buy New Target: $41 Upgrade
17/09/2018 Broker: JMP Securities Old Rating: Market Outperform New Rating: Market Perform Old Target: $34 Downgrade

RVNC touched $17.69 during the last trading session after $0.14 change.Currently Revance Therapeutics, Inc. is downtrending after 29.56% change in last February 15, 2018. RVNC has also 322,458 shares volume. The stock underperformed the S&P500 by 29.56%.

Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacturing, and commercialization of novel botulinum toxin products for various aesthetic and therapeutic indications.The company has $774.06 million market cap. The company's lead drug candidate is DaxibotulinumtoxinA for injection , which is in Phase III clinical trials to treat glabellar (frown) lines, as well as in Phase II clinical trials for the treatment of cervical dystonia and plantar fasciitis.Currently it has negative earnings. It is also developing DaxibotulinumtoxinA topical gel (RT001) that is in preclinical development.

For more Revance Therapeutics, Inc. (NASDAQ:RVNC) news announced recently go to: Benzinga.com, Seekingalpha.com, Seekingalpha.com, Streetinsider.com or Seekingalpha.com. The titles are as follows: “22 Stocks Moving In Thursday’s Pre-Market Session – Benzinga” announced on January 17, 2019, “Revance prices stock offering – Seeking Alpha” on January 17, 2019, “Revance Therapeutics appoints Tobin C. Schilke as CFO – Seeking Alpha” with a publish date: October 11, 2018, “Revance Therapeutics (RVNC) Announces Proposed Approx. $100M Common Share Offering – StreetInsider.com” and the last “Revance Therapeutics: A New Contender In The Botox Arena – Seeking Alpha” with publication date: September 10, 2018.